Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1186/ar2932. Epub 2010 Feb 12.
Affiliations
- PMID: 20152042
- PMCID: PMC2875659
- DOI: 10.1186/ar2932
Randomized Controlled Trial
Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial
Norman T M Ng et al. Arthritis Res Ther. 2010.
Abstract
Introduction: Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological therapies. Although walking is commonly recommended for reducing pain and increasing physical function in people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms and physical activity participation in people with mild to moderate hip or knee OA.
Methods: Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg glucosamine sulphate per day for 6 weeks, after which they began a 12-week progressive walking program, while continuing to take glucosamine. They were randomized to walk 3 or 5 days per week and given a pedometer to monitor step counts. For both groups, step level of walking was gradually increased to 3000 steps/day during the first 6 weeks of walking, and to 6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, physical function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness and physical function. Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week follow-ups. The Mann Whitney Test was used to examine differences in outcome measures between groups at each assessment, and the Wilcoxon Signed Ranks Test was used to examine differences in outcome measures between assessments.
Results: During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05). Between the start of the walking program (Week 6) and the final follow-up (Week 24), further improvements were seen in these outcomes (P < 0.05) although most improvements were seen between Weeks 6 and 12. No significant differences were found between walking groups.
Conclusions: In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms. A more robust study with a larger sample is needed to support these preliminary findings.
Trial registration: Australian Clinical Trials Registry ACTRN012607000159459.
Figures
Figure 1
Study design. GS, glucosamine sulphate.
Figure 2
Process of recruitment for the study. OA, osteoarthritis. PA, physical activity.
Figure 3
Compliance with the Stepping Out program. (a) The percentage of participants who complied with the number of 'walking' days per week of the walking program (Weeks 7 to 18 of the study). (b) Mean number of steps walked each 'walking' day during the 12-week Stepping Out program (Weeks 7 to 18 of the study).
Similar articles
- Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM. Schnitzer TJ, et al. JAMA. 2019 Jul 2;322(1):37-48. doi: 10.1001/jama.2019.8044. JAMA. 2019. PMID: 31265100 Free PMC article. Clinical Trial. - A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial.
Frestedt JL, Walsh M, Kuskowski MA, Zenk JL. Frestedt JL, et al. Nutr J. 2008 Feb 17;7:9. doi: 10.1186/1475-2891-7-9. Nutr J. 2008. PMID: 18279523 Free PMC article. Clinical Trial. - Strategies for managing osteoarthritis.
Ng NT, Heesch KC, Brown WJ. Ng NT, et al. Int J Behav Med. 2012 Sep;19(3):298-307. doi: 10.1007/s12529-011-9168-3. Int J Behav Med. 2012. PMID: 21614451 - Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis.
Bruyere O, Reginster JY. Bruyere O, et al. Drugs Aging. 2007;24(7):573-80. doi: 10.2165/00002512-200724070-00005. Drugs Aging. 2007. PMID: 17658908 Review.
Cited by
- The effects of a moderate exercise program on knee osteoarthritis in male wistar rats.
Fallah Mohammadi M, Hajizadeh Moghaddam A, Mirkarimpur H. Fallah Mohammadi M, et al. Iran J Basic Med Sci. 2013 May;16(5):683-8. Iran J Basic Med Sci. 2013. PMID: 23826489 Free PMC article. - Validity of the step test for exercise prescription: no extension to a larger age range.
Vidoni ED, Mattlage A, Mahnken J, Burns JM, McDonough J, Billinger SA. Vidoni ED, et al. J Aging Phys Act. 2013 Oct;21(4):444-54. doi: 10.1123/japa.21.4.444. Epub 2012 Dec 10. J Aging Phys Act. 2013. PMID: 23238135 Free PMC article. - Use of pedometer-driven walking to promote physical activity and improve health-related quality of life among meat processing workers: a feasibility trial.
Mansi S, Milosavljevic S, Tumilty S, Hendrick P, Baxter GD. Mansi S, et al. Health Qual Life Outcomes. 2013 Nov 1;11:185. doi: 10.1186/1477-7525-11-185. Health Qual Life Outcomes. 2013. PMID: 24175980 Free PMC article. Clinical Trial. - Impact of Physical Activity in Cardiovascular and Musculoskeletal Health: Can Motion Be Medicine?
Curtis GL, Chughtai M, Khlopas A, Newman JM, Khan R, Shaffiy S, Nadhim A, Bhave A, Mont MA. Curtis GL, et al. J Clin Med Res. 2017 May;9(5):375-381. doi: 10.14740/jocmr3001w. Epub 2017 Apr 1. J Clin Med Res. 2017. PMID: 28392856 Free PMC article. Review. - Reporting quality of interventions using a wearable activity tracker to improve physical activity in patients with inflammatory arthritis or osteoarthritis: a systematic review.
van Wissen MAT, Berger MAM, Schoones JW, Gademan MGJ, van den Ende CHM, Vliet Vlieland TPM, van Weely SFE. van Wissen MAT, et al. Rheumatol Int. 2023 May;43(5):803-824. doi: 10.1007/s00296-022-05241-x. Epub 2022 Dec 1. Rheumatol Int. 2023. PMID: 36454326 Free PMC article.
References
- Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35. - PMC - PubMed
- Access Economics. Painful Realities: The Economic Impact of Arthritis on Australia in 2007. Sydney: Arthritis Australia; 2007.
- Access Economics. The Prevalence, Cost, and Burden of Disease of Arthritis in Australia. Canberra, Australia: The Arthritis Foundation of Australia; 2001.
- American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis on the hip and knee. Arthritis Rheum. 2000;43:1905–1915. - PubMed
- Scott DL, Shipley M, Dawson A, Edwards S, Symmons DP, Woolf AD. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol. 1998;37:546–554. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources